Fletcher Payne Net Worth

The estimated Net Worth of Fletcher Payne is at least $5.1 Thousand dollars as of 19 September 2022. Fletcher Payne owns over 10,000 units of Catalyst Biosciences Inc stock worth over $5,100 and over the last 9 years Fletcher sold CBIO stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Fletcher Payne CBIO stock SEC Form 4 insiders trading

Fletcher has made over 5 trades of the Catalyst Biosciences Inc stock since 2015, according to the Form 4 filled with the SEC. Most recently Fletcher bought 10,000 units of CBIO stock worth $6,800 on 19 September 2022.

The largest trade Fletcher's ever made was buying 10,000 units of Catalyst Biosciences Inc stock on 19 September 2022 worth over $6,800. On average, Fletcher trades about 1,753 units every 137 days since 2015. As of 19 September 2022 Fletcher still owns at least 10,000 units of Catalyst Biosciences Inc stock.

You can see the complete history of Fletcher Payne stock trades at the bottom of the page.

What's Fletcher Payne's mailing address?

Fletcher's mailing address filed with the SEC is 260 Littlefield Ave, South San Francisco, CA 94080, USA.

Insiders trading at Catalyst Biosciences Inc

Over the last 9 years, insiders at Catalyst Biosciences Inc have traded over $2,614,728 worth of Catalyst Biosciences Inc stock and bought 81,771 units worth $199,380 . The most active insiders traders include Jeff Himawan, James E Deerfield Mgmt L.P...., and Augustine Lawlor. On average, Catalyst Biosciences Inc executives and independent directors trade stock every 62 days with the average trade being worth of $3,315. The most recent stock trade was executed by Nassim Usman on 9 August 2022, trading 3,250 units of CBIO stock currently worth $1,528.

What does Catalyst Biosciences Inc do?

catalyst is focused on developing novel medicines to address serious medical conditions for patients who need new or better treatment options. we used a scientific approach focused on protease-based therapeutic candidates to build a clinical-stage biopharmaceutical company whose current mission is to develop valuable therapies for patients with hemophilia. learn more about our hemophilia program. a protease is an enzyme that cleaves target proteins. learn more about proteases.

Complete history of Fletcher Payne stock trades at Aptose Biosciences Inc and Catalyst Biosciences Inc

Catalyst Biosciences Inc executives and stock owners

Catalyst Biosciences Inc executives and other stock owners filed with the SEC include:

• Nassim Usman,
  President, Chief Executive Officer, Director
• Dr. Nassim Usman Ph.D.,
  Pres, CEO & Director
• Howard Levy,
  Chief Medical Officer
• Dr. Howard Levy M.B.B.Ch., M.M.M., Ph.D.,
  Consultant
• Augustine Lawlor,
  Independent Chairman of the Board
• Errol De Souza,
  Independent Director
• Andrea Hunt,
  Independent Director
• Edward Williams,
  Independent Director
• Ana Kapor,
  IR Contact Officer
• Sharon Tetlow,
  Independent Director
• Geoffrey Ling,
  Independent Director
• Charles Democko,
  Senior Vice President - Regulatory Affairs
• Clinton Musil,
  Chief Financial Officer
• Dr. Tom Knudsen D.V.M., Ph.D.,
  Sr. VP of Corp. Devel.
• Dr. Grant Blouse M.Sc., Ph.D.,
  Chief Scientific Officer
• Seline Miller CPA,
  Sr. VP of Fin., Interim Chief Financial & Principal Accounting Officer
• John P Richard,
  Director
• Stephen A Hill,
  Director
• Edwin Madison,
  Chief Scientific Officer
• Fletcher Payne,
  Chief Financial Officer
• Harold E Selick,
  Director
• Group Ltd.Gni Hong Kong Ltd...,
  
• Seline E. Miller,
  SVP Finance; Interim CFO & PAO
• James E Deerfield Mgmt L.P....,
  
• Eddie Williams,
  Director
• Jeff Himawan,
  Director
• Veronica Cai,
  Controller
• Grant E. Blouse,
  Chief Scientific Officer
• Jeanne Y Jew,
  Director
• Hong Kong Ltd Gni,